Once the Borrelia burgdorferi bacterium is in the body, it starts to change its form by altering the proteins on its outer cell wall, effectively hiding itself from the immune system
CJC-1295 is a long-acting compound that binds to albumin in the blood, allowing it to stay in the system for about 6-8 days after a single injection, leading to sustained increases in GH and IGF-1
Vyleesi (bremelanotide) was FDA-approved in June 2019 for HSDD in premenopausal women based on Phase 3 clinical trial data
The FDA has issued safety communications regarding compounded GLP-1 receptor agonists, including tirzepatide and semaglutide, warning about adverse events from bacterial contamination, incorrect dosing, and use of improper ingredients
Incorporating a balanced diet, regular physical activity, and behavioral changes enhances the benefits of these medications and supports long-term weight loss and maintenance